Quantcast

Latest glioblastoma multiforme Stories

2014-07-25 23:03:18

Harvard Neuro-Oncologist presents latest brain tumor research and treatment options at American Brain Tumor Association’s annual conference. Chicago, IL (PRWEB) July 25, 2014 Progress in understanding the molecular genetics of brain tumors has ushered in a new era of promising brain tumor treatments, according to Patrick Wen, MD, professor of neurology, Harvard Medical School, director of the Center for Neuro-Oncology, Dana-Farber Cancer Institute. At the American Brain Tumor...

2014-07-24 16:27:44

Company's fiscal year will change from December 31 to June 30 VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today that the company's board of directors approved a change of the company's fiscal year from December 31 to June 30. Accordingly, DelMar will file a Transition Form 10K on or before September 30, 2014. Jeffrey Bacha, president and CEO of DelMar stated, "The...

2014-07-16 08:28:30

DCVax®-Direct Phase II Trial Preparations and Manufacturing Expansion Underway BETHESDA, Md., July 16, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Phase I portion of the Company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment, and the Company is now underway with preparations for the Phase II...

2014-07-15 08:28:28

Eighty Percent of Patients Treated with G-202 had No Tumor Growth at Two Months SAN ANTONIO, July 15, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the APPLE 2014 presentation. Devalingam Mahalingam, MD, PhD, Principal Investigator of the G-202 Phase II trial in hepatocellular carcinoma (HCC) patients, presented the HCC clinical trial update for G-202 at the 5(th) Asia-Pacific Primary Liver...

2014-07-15 08:28:10

Physicians at 15 leading brain cancer centers in 8 countries certified to provide NovoTTF Therapy to recurrent glioblastoma patients on prescription order LUCERNE, Switzerland, July 15, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that 18 prominent neurosurgeons and neuro-oncologists at medical centers in Europe and Israel are trained and certified to prescribe NovoTTF Therapy. These physicians will now be able to treat recurrent glioblastoma...

2014-07-14 08:26:37

SAN ANTONIO, July 14, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company. Sheldon S. Traube, Director of Research, Kareg Corporation, Initiating Coverage with a Speculative Buy Recommendation Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf...

2014-07-12 23:02:37

ResearchMoz presents this most up-to-date research on Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive Market. View All Therapeutic Area Market Research Reports at http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) July 12, 2014 “Critical Care Therapeutics in Major Developed Markets to 2020 - New and Late-Stage Four-Factor PCCs and Recombinant Products to Drive...

2014-07-11 23:09:19

Capital Institute for Neurosciences Begins Clinical Trial Delivering Chemotherapy Directly to Brain Tumors Starting with Incision in Leg Hopewell, NJ (PRWEB) July 11, 2014 The Capital Institute for Neurosciences at Capital Health today announced it has performed the first procedure in a clinical trial that delivers chemotherapy to brain tumors through a catheter inserted in the leg. During the procedure, done at Capital Health Medical Center – Hopewell, Dr. Erol Veznedaroglu, an...

2014-07-09 11:17:04

NIH/National Institute of Neurological Disorders and Stroke NIH-funded researchers find brain tumor cells disrupt the brain's protective barrier, offering potential avenues for therapy Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain's protective barrier, a study in mice indicates. This finding could ultimately lead to new ways to bring about the death of the tumor, as therapies may be able to reach these...

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'